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events that she might blame for her misfortune. The other con-
trol group was the Collaborative Perinatal Project population.
Although these women had been interviewed during pregnancy
and so had not had as much time as the other controls to for-
get, they too lacked the incentive the cases’ mothers had to
recall events in early pregnancy, and being a relatively under-
privileged group (55% Black or Puerto Rican’) they are less
likely to have ever known what their body temperature was
during any fever.
Secondly, Miller et al. suggest that published work favours
the view that local outbreaks of febrile illness and of anen-
cephaly tend to be associated-but two of the four papers they
cite in this connection2,3 only mention associations involving
about four anencephalics each, and the other tw04.5 do not
mention epidemics of febrile illness at all but deal exclusively
with increases in the frequency of neural-tube defects which
lasted several years. No mention is made of other published
work in which several very large series of live and still births
occurring 26-40 weeks after influenza epidemics (including
well over a thousand anencephalics in all) were compared with
births in the same places at other times in respect of the fre-
quency of various malformations-with results that were com-
pletely negative for anencephaly.6,7
Another population that seems to be at increased risk of
hyperthermia but not of anencephaly is that of Finland, the
home of the sauna, where less than 0-6/1000 births were
reported to be anencephalic.8
Especially in the light of the research on other species cited
by Miller et al., their hypothesis that hyperthermia can cause
anencephaly in man may merit further testing; but the above
features of their control groups and of the population studies
cited make this hypothesis less convincing than Miller et al.
suggest.
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PLASMAPHERESIS IN RAYNAUD’S DISEASE
SIR,-Dr Talpos and his colleagues (Feb. 25, p. 416) report
dramatic improvement after plasmapheresis in four cases of
Raynaud’s phenomenon with ulceration of the digits. Since
this syndrome is seen in a heterogeneous group of conditions
of which sclerodactyly with telangiectasia and calcinosis
(C.R.S.T. syndrome)9 is perhaps the most common, it would be
helpful in evaluating the report to have more information
about the clinical signs and the results of the tests for autoim-
mune antibodies in the patients.
Southampton General Hospital,
Southampton SO9 4XY E. D. ACHESON
*** This letter has been shown to Dr Talpos and his colleagues
whose reply follows.&mdash;Eo.L.
SIR,-Two of our five patients were diagnosed as having
scleroderma on the basis of constitutional symptoms, severe
Raynaud’s phenomenon, abnormal cesophageal motility and
abnormal antinuclear-antibody patterns. Neither shows the
C.R.S.T. variant of scleroderma to which Professor Acheson
refers. We have yet to detect any underlying disease in the
other three patients.
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The nomenclature of small-vessel disease of the extremities
is confused. The terms Raynaud’s disease and Raynaud’s phe-
nomenon are often used interchangeably, and some writers
attempt to divide them into primary and secondary to classify
better the clinical signs we so easily recognise.
All five patients have minor increase of at least one of the
three immunoglobulins which we measure (IgA, IgG, and
IgM). These increases average about 15 % above the upper limit
of normal with a maximum increment of less than twice nor-
mal. Caution is necessary in interpreting this, however,
because we have not determined what abnormalities, if any,
would be present in a group of matched patients with
cutaneous ulcers but without Raynaud’s symptoms. Other rou-
tine tests have been unremarkable.
Clinically the five patients are slowly regressing to their pre-
treatment state, although they all are much improved. One pa-
tient with scleroderma who underwent plasmapheresis last
summer for pregangrenous changes of an entire index finger
eventually lost a small amount of finger pulp. She had a
further three plasma exchanges, all averaging 70% total
plasma volume, when her index finger began to deteriorate
with the winter cold. Since then her condition has stabilised.
The clinical course of these patients leads us to believe that
plasmapheresis is a valuable form of therapy for certain pa-
tients. Better treatment will be forthcoming when the mechan-
ism for the efficacy of this therapy has been elucidated. We
hope to answer some of these questions at the conclusion of our
formal trial.
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IMMUNE COMPLEXES AND PROGNOSIS OF
HUMAN BREAST CANCER
SiR,-We have found’ that sequential determination of cir-
culating immune complexes (c.i.c.) confirms the clinico-
pathological prognosis in breast cancer. In patients with good
prognosis (no lymph-node involvement detectable at mastec-
tomy) c.i.c. values fell to normal range twelve months after
the operation whilst the c.i.c. value remained high in patients
with poor prognosis (metastases in apical axillary and/or inter-
nal mammary lymph-nodes at mastectomy) and in those who
died from cancer within 22 months of the operation.
We now have results on 83 patients and have found a simi-
lar pattern of c.i.c. values varying according to clinico-
pathological prognosis or death (figure a).
When c.i.c. levels were evaluated by outcome (dead or alive)
12-48 months after mastectomy (figure b) the correlation with
prognosis assessed clinicopathologically had disappeared. By
contrast, patients both with good and poor prognosis who are
still alive displayed preoperatively similar c.i.c. levels which
decreased postoperatively to almost normal levels. Patients
who died during the follow-up period, had, both preoperatively
and postoperatively, c.i.c. levels (p<0.05) significantly higher
than those of the survivors. Again, there was no difference
between patients with good and poor prognosis. Furthermore,
the postoperative decrease in c.i.c. was not significant.
Figure c covers patients followed up for 24 months after
mastectomy and those of intermediate prognosis (metastases
only in lower axillary lymph-nodes); patients given chemo-
therapy within 12 months of mastectomy have been excluded
because this treatment reduces c.i.c. levels in animals. (unpub-
lished). Regardless of clinicopathological staging, patients who
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